• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Serine protease inhibitor Kazal-type 2 (SPINK2)

ACP24159

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP24159 Target NameSPINK2
Target SynonymsSPINK2Serine protease inhibitor Kazal-type 2; Acrosin-trypsin inhibitor; Epididymis tissue protein Li 172; HUSI-IIFormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range24-84
Protein LengthFull Length of Mature ProteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDP20155
Background Information
  • Uniprot Id

    P20155

  • Target Species

    Human

  • Target Name

    SPINK2

  • Target Full Name

    Serine protease inhibitor Kazal-type 2

  • Target Function

    As a strong inhibitor of acrosin, it is required for normal spermiogenesis. It probably hinders premature activation of proacrosin and other proteases, thus preventing the cascade of events leading to spermiogenesis defects. May be involved in the regulation of serine protease-dependent germ cell apoptosis. It also inhibits trypsin.

  • Target Subcellular Location

    Secreted. Cytoplasmic vesicle, secretory vesicle, acrosome.

  • Target Tissue Specificity

    Expressed in epididymis (at protein level).

  • Target Synonyms

    SPINK2Serine protease inhibitor Kazal-type 2; Acrosin-trypsin inhibitor; Epididymis tissue protein Li 172; HUSI-II

Inquire Recombinant Human Serine protease inhibitor Kazal-type 2 (SPINK2) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification